Finance

Lists
524715:BOM
Sun Pharmaceutical Industries Ltd
1 760,00 ₹
-0,03%
(-0,60) 1D
16 қаз., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524715...
Open
1 759,60 ₹
High
1 764,40 ₹
Low
1 744,85 ₹
Mkt. cap
4,22 трлн
Avg. vol.
97,37 мың
Volume
35,68 мың
Dividend
0,91%
Quarterly dividend
4,00 ₹
Ex-dividend date
2026 ж. 07 шіл.
P/E ratio
34,89
52-wk high
2 047,55 ₹
52-wk low
1 583,60 ₹
EPS
50,44 ₹
Shares outstanding
0,00
No. of employees
47 мың
Open
1 759,60 ₹
High
1 764,40 ₹
Low
1 744,85 ₹
Mkt. cap
4,22 трлн
Avg. vol.
97,37 мың
Volume
35,68 мың
Dividend
0,91%
Quarterly dividend
4,00 ₹
Ex-dividend date
2026 ж. 07 шіл.
P/E ratio
34,89
52-wk high
2 047,55 ₹
52-wk low
1 583,60 ₹
EPS
50,44 ₹
Shares outstanding
0,00
No. of employees
47 мың
News stories
From web sources and news partners
Profile
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
About Sun Pharmaceutical Industries Ltd
CEO-
Employees47 мың
Founded1983
HeadquartersGoregaon East, Мумбаи, Үндістан
SectorPharmaceutical industry
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
144,78 млрд
155,21 млрд
146,12 млрд
153,00 млрд
Cost of goods sold
29,83 млрд
29,45 млрд
37,36 млрд
29,63 млрд
Cost of revenue
29,83 млрд
29,45 млрд
37,36 млрд
29,63 млрд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,65 млрд
28,92 млрд
30,60 млрд
32,27 млрд
Operating expense
81,28 млрд
85,13 млрд
80,66 млрд
87,80 млрд
Total operating expenses
111,11 млрд
114,58 млрд
118,02 млрд
117,43 млрд
Operating income
33,67 млрд
40,62 млрд
28,10 млрд
35,57 млрд
Other non operating income
4,70 млрд
5,79 млрд
-14,29 млрд
7,24 млрд
EBT including unusual items
41,55 млрд
42,07 млрд
35,37 млрд
40,89 млрд
EBT excluding unusual items
41,55 млрд
46,97 млрд
26,83 млрд
42,93 млрд
Income tax expense
10,31 млрд
8,26 млрд
8,28 млрд
11,88 млрд
Effective tax rate
24,80%
19,63%
23,40%
29,05%
Other operating expenses
46,34 млрд
48,89 млрд
42,30 млрд
48,14 млрд
Net income
31,18 млрд
33,69 млрд
27,14 млрд
28,95 млрд
Net profit margin
21,54%
21,71%
18,57%
18,92%
Earnings per share
13,00
15,48
11,30
12,71
Interest and investment income
-
-
9,74 млрд
-
Interest expense
-998,60 млн
-783,60 млн
-858,90 млн
-996,70 млн
Net interest expenses
-998,60 млн
-783,60 млн
8,89 млрд
-996,70 млн
Depreciation and amortization charges
7,30 млрд
7,32 млрд
7,75 млрд
7,39 млрд
EBITDA
40,82 млрд
46,53 млрд
34,86 млрд
42,32 млрд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары